Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Nutr Res. 2014 Jul;34(7):585-94. doi: 10.1016/j.nutres.2014.06.010. Epub 2014 Jun 24.

Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer.

Author information

1
Division of Colorectal Surgery, Department of Surgery, China Medical University Hospital, Taichung, Taiwan. Electronic address: wtchen@mail.cmuh.org.tw.
2
Division of Medical Oncology in the Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan and Chang Gung University College of Medicine, Taoyuan, Taiwan.
3
Division of Colorectal Surgery, Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.
4
Division of Colon and Rectal Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
5
Division of Colorectal Surgery, Department of Surgery, China Medical University Hospital, Taichung, Taiwan.
6
Division of Colon and Rectal Surgery, Jia-Yi St Martin de Porres Hospital, Chiayi, Taiwan.
7
Department of Colorectal Surgery, Taipei Buddhist Tzu Chi General Hospital, Taipei, Taiwan.
8
Institute of Biochemical Sciences, National Taiwan University College of Life Science and Institute of Toxicology of Medicine National Taiwan University, Taipei, Taiwan; Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.

Abstract

Natural products, such as fermented soybeans, have been used to treat various physical conditions, including cancer. MB-6 is a botanical preparation composed of fermented soybean extract, green tea extract, Antrodia camphorata mycelia, spirulina, grape seed extract, and curcumin extract. Based on this, we hypothesized that MB-6 would increase the effectiveness of chemotherapy in patients with colon cancer. In a rodent study, MB-6, in combination with leucovorin/5-fluorouracil chemotherapy, increased the survival rate and life span of colon cancer tumor-bearing BALB/c mice as compared with treatment with chemotherapy alone. In a proof-of-concept clinical study, 72 patients with metastatic colorectal cancer were randomized to receive leucovorin, 5-fluorouracil, and oxaliplatin in combination with either MB-6 or placebo for 16 weeks. The primary outcome was the best overall response, and secondary outcomes included progression-free survival, overall survival, and adverse effects. Up to 77 weeks after treatment, there was follow-up with the patients. No significant difference in the best overall response rate and overall survival was observed between the 2 groups. Patients in the MB-6 group had a significantly lower disease progression rate than patients in the placebo group, during the study period (0.0% vs 15.8%, P = .026). The placebo group had a significantly higher incidence of adverse events at least grade 4 compared with the MB-6 group (28.9% vs 2.9%, respectively, P = .004) and a significantly higher occurrence of increased serum creatinine compared with the MB-6 group (29% vs 5.9%, P = .014). MB-6 is a promising botanical supplement that may increase the effectiveness of chemotherapy in patients with metastatic colorectal cancer.

KEYWORDS:

BALB/c mice; Herbal medicine; MB-6; Metastatic colorectal cancer; Overall survival; Progression-free survival; Tolerability

PMID:
25150117
DOI:
10.1016/j.nutres.2014.06.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center